GlassScriptPhysician profile
Kyle M Schaub
NPI 1679682777
$3,441.65
in general payments reported to CMS, 2019-2025
20 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $163 · 2021: $345 · 2022: $503 · 2023: $532 · 2024: $257 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $490.38 | 2019-2025 | Tryptyr, Total30, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $488.74 | 2024-2025 | Xdemvy |
| Abbvie INC. | $267.10 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Allergan, INC. | $257.63 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $250.13 | 2019-2024 | Acuvue |
| Rxsight INC | $245.81 | 2022-2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $242.85 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $180.83 | 2025 | Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $161.08 | 2019 | |
| Bausch & Lomb Americas INC. | $149.80 | 2022-2025 | Vyzulta, Scoutpro Osmolarity System, Miebo |
| Ivantis, INC | $135.99 | 2021 | |
| Dompe US, INC. | $122.85 | 2021 | |
| Apellis Pharmaceuticals, INC. | $106.49 | 2023 | Syfovre |
| Lombart Brothers, INC. | $92.72 | 2020 | |
| Novartis Pharmaceuticals Corporation | $67.62 | 2019-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $55.37 | 2023-2025 | Cequa |
| Harrow Eye, LLC | $42.39 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $37.99 | 2022-2024 | Dextenza |
| Coopervision INC. | $27.22 | 2020-2023 | Myday Contact Lens |
| Omeros Corporation | $18.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Schaub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.